Stay current on the latest developments from agencies including the CFPB, Federal Reserve, FDIC, and OCC to advise clients on real-life regulatory situations.
Quest Diagnostics Inc. beat back a lawsuit alleging it monopolized the Northern California market for medical diagnostic testing after a federal appeals court agreed the complaint lacks merit.
The suit is likely over. The U.S. Court of Appeals for the Ninth Circuit, in a Feb. 12 unpublished opinion, affirmed a lower court’s ruling that the plaintiffs showed no facts to support their case. To revive their claims, they would have to convince the U.S. Supreme Court to revisit the case, an extremely high bar.
The plaintiffs paid copayments and deductibles on lab work done at Quest. They alleged that Quest monopolized two markets by paying kickbacks to doctors, colluding with two major private health insurers, and acquiring competing labs to eliminate them as competitors. They also alleged that Quest illegally tied products together in its fee structure.
The trial judge dismissed the suit with prejudice in April 2016, saying the plaintiffs failed on three attempts to plead a believable monopolization claim against Quest.
Ninth Circuit Judges Sidney Thomas, William Fletcher, and Richard Paez agreed. They said the plaintiffs didn’t provide facts to support any of their three theories for how Quest restricted patients from using other diagnostic labs.
The case is Eastman v. Quest Diagnostics Inc. , 2018 BL 47376, 9th Cir., 16-15793, 2/12/18
To contact the reporter on this story: Eleanor Tyler in Washington at email@example.com
To contact the editor responsible for this story: Fawn Johnson at firstname.lastname@example.org
The court's opinion is at http://src.bna.com/wn8.
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)